UroGen Pharma Ltd. (URGN) Gross margin 2016–2025
UroGen Pharma Ltd. (URGN) gross margin by fiscal year — reported gross profit divided by reported revenue.
88.7%FY2025 · since FY2016: 99.8% → 88.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 88.7% | -1.5 pp |
| FY2024 | 90.2% | +1.5 pp |
| FY2023 | 88.7% | +0.6 pp |
| FY2022 | 88.1% | -1.2 pp |
| FY2021 | 89.3% | -2.2 pp |
| FY2020 | 91.4% | -8.6 pp |
| FY2019 | 100.0% | +159.8 pp |
| FY2018 | -59.8% | -152.5 pp |
| FY2017 | 92.6% | -7.2 pp |
| FY2016 | 99.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Operating incomeURGN Operating marginURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →